Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Open access
Eichhorst, Barbara, Niemann, Carsten U., Kater, Arnon P., Fürstenau, Moritz, von Tresckow, Julia, Zhang, Can, Robrecht, Sandra, Gregor, Michael, Juliusson, Gunnar, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Lindström, Vesa, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian B., Illmer, Thomas, Schöttker, Björn, Nösslinger, Thomas, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Frederiksen, Henrik, van der Klift, Marjolein, Jäger, Ulrich, Leys, Maria B.L., Hoogendoorn, Mels, Lotfi, Kourosh, Hebart, Holger, Gaska, Tobias, Koene, Harry, Enggaard, Lisbeth, Goede, Jereon, Regelink, Josien C., Widmer, Anouk, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl A., Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Levin, Mark-David, van Oers, Marinus, Geisler, Christian, Stilgenbauer, Stephan, Hallek, Michael·2023·New England Journal of Medicine

Abstract

Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Download a PDF of the Research Summary. In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) or 12 cycles of venetoclax–rituximab, venetoclax–obinutuzumab, or venetoclax–obinutuzumab–ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, <10−4 [i.e., <1 CLL cell in 10,000 leukocytes]) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival. A total of 926 patients were assigned to one of the four treatment regimens (229 to chemoimmunotherapy, 237 to venetoclax–rituximab, 229 to venetoclax–obinutuzumab, and 231 to venetoclax–obinutuzumab–ibrutinib). At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax–obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax–obinutuzumab–ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons), but it was not significantly higher in the venetoclax–rituximab group (57.0%; 97.5% CI, 49.5 to 64.2; P=0.32). Three-year progression-free survival was 90.5% in the venetoclax–obinutuzumab–ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001). Progression-free survival at 3 years was also higher with venetoclax–obinutuzumab (87.7%; hazard ratio for disease progression or death, 0.42; 97.5% CI, 0.26 to 0.68; P<0.001), but not with venetoclax–rituximab (80.8%; hazard ratio, 0.79; 97.5% CI, 0.53 to 1.18; P=0.18). Grade 3 and grade 4 infections were more common with chemoimmunotherapy (18.5%) and venetoclax–obinutuzumab–ibrutinib (21.2%) than with venetoclax–rituximab (10.5%) or venetoclax–obinutuzumab (13.2%). Venetoclax–obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA–CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.) QUICK TAKE VIDEO SUMMARYVenetoclax Combinations in CLL 02:52

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2213093

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Metadata

Authors
Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., Janssens, A., Christiansen, I., Baumann, M., Frederiksen, H., van der Klift, M., Jäger, U., Leys, M. B. L., Hoogendoorn, M., Lotfi, K., Hebart, H., Gaska, T., Koene, H., Enggaard, L., Goede, J., Regelink, J. C., Widmer, A., Simon, F., De Silva, N., Fink, A.-M., Bahlo, J., Fischer, K., Wendtner, C.-M., Kreuzer, K. A., Ritgen, M., Brüggemann, M., Tausch, E., Levin, M.-D., van Oers, M., Geisler, C., Stilgenbauer, S., & Hallek, M.
Venue
New England Journal of Medicine
Published
2023-05-11
Volume
388
Issue
19
Pages
1739-1754
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4376108172
Cited by
305
References
26
FWCI
43.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1056/nejmoa2213093
The paper
Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., . . . Hallek, M. (2023). First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2213093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.